Breaking news

In order to inform the neurological community and patients, the Italian Association of the Peripheral Nervous System (ASNP), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Society of Neurology (SIN) have developed a joint document to guide best practice for managing patients with immune-mediated neuropathy during the global spread of COVID-19.

This paper, recently published in Revue Neurologique, summarises recommendations for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS).

In this consensus statement recently published in Neuro-Oncology, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGG) during the COVID-19 pandemic.

Most medical centres are postponing elective procedures and deferring non-urgent clinic visits to conserve hospital resources and prevent spread of COVID-19.

In this review, the authors explore the risk of COVID-19 in PD patients in terms of susceptibility to severe disease, impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak.

In this correspondence recently published in Lancet Neurology, the authors report the results of the pilot phase of an investigation of effects of COVID-19 among Italian people with multiple sclerosis, based on a core dataset collected from treatment providers through a specifically designed web-based case report form.

In this paper, the authors report a patient treated with natalizumab for relapsing-remitting MS who developed COVID-19 and recovered in a few days without complications.

In this case report recently published in Neurology, Barzegar et al. present the case of a 42-year-old woman affected by relapsing-remitting MS treated with fingolimod who was diagnosed with COVID-19 and had a favourable outcome.

In this retrospective multicentre cohort study, just published in JAMA, the authors describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19.

In this multicentre, prospective, open-label, randomised, phase 2 trial the authors assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.

In this observational study recently published in the New England Journal of Medicine, the authors examined the association between hydroxychloroquine use and intubation or death at a large medical centre in New York City.

In this Viewpoint recently published in Lancet Rheumatology, the authors summarised the immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.

The objective of this prospective cohort study was to validate and compare clinical findings with data from medical autopsy, virtual autopsy, and virological tests of 12 patients who died with a polymerase chain reaction– confirmed diagnosis of COVID-19.

The pandemic of COVID-19 continues to affect much of the world. Knowledge of diagnostic tests for SARS-CoV-2 is still evolving, and a clear understanding of the nature of the tests and interpretation of their findings is important.

In this paper published in Neurology, the authors conducted a scoping review of available literature on COVID-19 to assess the potential impact on neurologists in terms of prevalent comorbidities and incidence of new neurological events in patients hospitalized with COVID-19.